Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28235928 | 0.83 | MMP1 (0.36) | CA1CA2CA7CTSKCA12 | |
| SCHEMBL28705194 | 0.79 | DGAT1 (0.34) | CA2TSHRLMNACYP3A4NFKB1 | |
| SCHEMBL6379683 | 0.79 | DGAT1 (0.34) | CTSKTSHRTDP1DGAT1NOS1 | |
| SCHEMBL26288046 | 0.77 | TSHR (0.37) | CTSKTSHRRAB9ACA12CA14 | |
| SCHEMBL23746404 | 0.77 | DGAT1 (0.42) | CA12CA14DGAT1 | |
| SCHEMBL3808762 | 0.77 | CRBN (0.34) | CTSKDGAT1 | |
| SCHEMBL3808765 | 0.77 | CRBN (0.34) | CTSKDGAT1 | |
| SCHEMBL17348031 | 0.76 | DGAT1 (0.33) | LMNADGAT1 | |
| SCHEMBL601562 | 0.76 | MAOA (0.36) | CA1CA2CA7CTSKNFKB1 | |
| SCHEMBL3728300 | 0.76 | MAOA (0.36) | CA1CA2CA7CTSKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686990-B1 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2012-09-19 | — | — | EP | claimed |
| EP-1686990-A4 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2009-06-03 | — | — | EP | claimed |
| US-7101902-B2 | 2-guanidinylimidazolidinedione compounds and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2006-09-05 | — | — | US | claimed |
| EP-1686990-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. Army Medical Research and Materiel Command (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005072082-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | ARMY, UNITED STATES | 2005-07-07 | — | — | US | claimed |
| EP-1686990-B1 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-1686990-A4 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7101902-B2 | 2-guanidinylimidazolidinedione compounds and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1686990-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. Army Medical Research and Materiel Command (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005072082-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | ARMY, UNITED STATES | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | GUCY1B2, GUCY1A2, AGK | CA1 4807/4885CA2 2497/4885CA7 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.